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Mice treated with a single injection of formalin-fixed Coxiella burnetii showed a significant increase in resistance to vaccinia virus (VV)
infection compared to untreated mice. C. burnetii stimulated dramatically high levels of nitric oxide (NO) in the serum of treated mice,
suggesting that NO might play a role in resistance to virus infection. To test this hypothesis, the effect of C. burnetii treatment on VV
replication was examined in NOS2/ and wild-type mice. C. burnetii treatment inhibited VV replication in both the knockout and wild-type
mice but the effect was significantly greater in the NOS2/ mice. Experiments in IFNg receptor knockout mice indicated that the
nonspecific antiviral immunity induced by C. burnetii was dependent on IFNg and not NO. In the absence of NO, indoleamine 2,3-
dioxygenase (IDO) was increased in C. burnetii-treated mice and this may contribute to the accelerated virus clearance in NOS2/ mice.
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Coxiella burnetii is a rickettsia-like organism that is a
common pathogen of wildlife and domesticated livestock. It
is the causative agent of the debilitating zoonosis, Q fever
(Aitken et al., 1987; Kovacova and Kazar, 2002). The
formalin-fixed whole cell preparation of this agent has been
shown to induce potent, nonspecific antiviral effects when
given to experimental animals before challenge. Thus, Waag
et al. (1990) showed this preparation [often called the
complement fixing antigen of Q fever, abbreviated to
Q fever antigen (QFA)] would protect against lethal infec-
tions of encephalomyocarditis virus (EMCV), rift valley
fever virus (RVFV), and Banzi virus in mice. This whole
cell preparation has also been shown to induce profound
resistance to bacterial (Kelly, 1977) and protozoal infections
(Clark, 1979; Zvilich et al., 1995a). Subcellular fractions of
C. burnetii are also effective at inducing nonspecific anti-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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Street, Darlington, Sydney, NSW 2010, Australia.viral activity in mice. For example, Zvilich et al. (1995a)
showed that a chloroform–methanol residue (CMR) made
from phase I C. burnetii whole cells protected mice from
RVFV infection. The protective effect was subsequently
shown to be dependent upon interferons (IFNs), that is,
both IFNg and IFNa/h (Zvilich et al., 1995b).
In view of the importance of IFNs in this resistance to
virus infection, it seemed reasonable to ask whether nitric
oxide (NO), a downstream effector molecule induced by
IFNg, might contribute to the protective effect induced by
C. burnetii against virus infection. The high levels of NO
produced by NOS2 have been shown to play a role in host
defense against a wide range of intra- and extracellular
pathogens including Leishmania major (Liew et al., 1990),
Trypanosoma cruzi (Mun˜oz-Ferna´ndez et al., 1992), and
Mycobacterium tuberculosis (Chan et al., 1992). More
recently, reports have appeared showing that NO may play
a role in the immune response to C. burnetii itself (Howe
et al., 2002; Zamboni and Rabinovitch, 2003). Perhaps more
importantly, it has been shown that NO can mediate antiviral
effects both in vitro (Bi and Reiss, 1995; Croen, 1993) and
in vivo (Karupiah et al., 1993). Viruses in these studies
include herpes simplex virus type-1 (HSV-1) (Croen, 1993),
ectromelia virus (EV) (Karupiah et al., 1993), vaccinia virus
Table 2
Role of NO in nonspecific antiviral immunity induced by QFA
Wild type NOS2/
Plasma
nitrate (AM)
log10
virus titre
Plasma
nitrate (AM)
log10
virus titre
Control 9.4 F 0.9 – 3.7 F 0.4 –
QFA 198.9 F 39.7 – 3.0 F 0.4 –
VV 10.2 F 1.8 7.1 F 0.2 2.9 F 0.2 7.0 F 0.1
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(FV) (Akarid et al., 1995).
In this investigation, we have found that: (i) QFA induces
a potent antiviral response in mice to vaccinia virus; (ii)
treatment with QFA is followed by a large increase in
systemic NO production; and (iii) this increase in NO
production does not contribute to the antiviral effect induced
by QFA but appears to detract from it.
QFA + VV 245.1 F 66.1 4.5 F 0.7 2.5 F 0.4 <2
Wild-type and NOS2/ mice were treated intraperitoneally with 100 Al
QFA 10 days before infection with 107 PFU VV iv. Other groups of PBS-
and QFA-treated mice were left uninfected. At 3 days postinfection, the
mice were sacrificed for determination of plasma nitrate concentration and
viral load in the ovaries. Results are mean F SEM, n = 4 mice per group.
This experiment is representative of three similar experiments.Results and discussion
Following intraperitoneal injection of 200 Al of a 1/4
dilution of QFA, C57BL/6 mice produced high levels of
nitric oxide, as measured by plasma nitrate concentration.
Plasma nitrate was significantly elevated at 1, 2, 4, and 6
weeks posttreatment (P < 0.05) and had returned near to
baseline by 8 weeks (data not shown). Peak plasma nitrate
levels were observed 2 weeks following treatment. There-
fore, in all subsequent experiments mice were treated intra-
peritoneally with a standard dose of 200 Al of QFA diluted
1/4 in PBS. Ten days following treatment with QFA, mice
were infected with VV.
C57BL/6 mice were treated with QFA and infected
intravenously with 107 pfu VV. Three days following
infection, the mice were sacrificed for determination of
virus titres and plasma nitrate. Plasma nitrate levels were
significantly elevated in all mice that had been treated with
QFA (P < 0.001), and infection with VV did not result in
further elevation in plasma nitrate concentration (Table 1).
Viral load in the ovaries of QFA-treated mice was approx-
imately 10000-fold lower than that found in untreated mice
infected with VV (Table 1). At times later than 3 days
postinfection, virus was generally not recoverable from the
ovaries of QFA-treated mice (data not shown).
To investigate the role of NO in the nonspecific antiviral
immunity induced by QFA, experiments were performed
using NOS2/ mice. In these experiments, wild-type and
NOS2/ mice were treated with QFA as before, infected
with VV and sacrificed 3 days postinfection. Using this
protocol, plasma nitrate levels in the wild-type mice wereTable 1
Induction of potent antiviral immunity following treatment of mice with
QFA
Plasma nitrate (AM) log10 virus titre
Control 7.8 F 2.0 –
QFA 548.7 F 62.2a –
VV 13.4 F 4.7 7.6 F 0.2
QFA + VV 696.0 F 82.2a 2.9 F 0.4b
Female C57BL/6 were treated intraperitoneally with QFA and 10 days later
infected intravenously with 107 PFU VV. Mice were sacrificed 3 days
postinfection for determination of viral load in the ovaries and plasma
nitrate concentration. Results are mean F SEM, n = 4 mice per group. This
experiment is representative of >5 similar experiments.
a P < 0.0001 compared to uninfected mice.
b P < 0.0001 compared to untreated mice infected with VV.greatly elevated and considerable antiviral activity was
evident (Table 2). As expected, plasma nitrate levels were
not elevated in QFA-treated NOS2/ mice. However,
ovary virus titres in these mice were considerably reduced
(below the limit of detection of log10 2) in comparison to
similarly treated wild-type mice (Table 2). Similar results
were obtained for virus titres in the lung. QFA-treated wild-
type mice showed a log10 1.4 decrease in virus titres in the
lung compared to untreated mice. In contrast, QFA treat-
ment in NOS2/ mice resulted in a log10 3.5 decrease in
lung titres. These findings show that nonspecific antiviral
immunity triggered by QFA is not only not dependent upon
NO but is, in fact, more potent in the absence of NO.
Previous studies have suggested that NO can down-
regulate some aspects of the immune response including
the production of IFNg (Cochrane et al., 2001; Florquin
et al., 1994; Van der Meide et al., 1995). Since it has been
shown that IFNg appears to play a role in Coxiella-mediated
protection against RVFV (Zvilich et al., 1995b), levels
of circulating IFNg were measured in VV-infected,
QFA-treated wild-type and NOS2/ mice. IFNg levels
were significantly increased in plasma from VV-infected,
QFA-treated NOS2/ mice compared to similarly treated
wild-type mice (Table 3) and may contribute to the en-
hanced virus clearance in NOS2/ mice.Table 3
Plasma IFNg levels following nonspecific antiviral immunity induced by
QFA
IFNg (pg/ml)
Wild type NOS2/
Control ND ND
QFA 75 F 4 102 F 4
VV 39 F 2 53 F 3
QFA + VV 111 F 22a 218 F 3a,b
Wild-type and iNOS/ mice were treated with QFA 10 days before
infection with 107 PFU VV iv. Other groups of PBS- and QFA-treated mice
were left uninfected. At 3 days postinfection, the mice were sacrificed for
determination of plasma IFNg concentration. Results are meanF SEM, n =
3 mice per group. ND, not detected.
a P < 0.005 compared to untreated VV-infected mice.
b P < 0.01 compared to QFA + VV wild-type mice.
Table 4
Role of IFNg in nonspecific antiviral immunity induced by QFA
Wild type IFNgR/
Plasma
nitrate (AM)
log10
virus titre
Plasma
nitrate (AM)
log10
virus titre
Control 5.7 F 0.8 – 5.9 F 0.9 –
QFA 214.5 F 23.4 – 6.8 F 0.4 –
VV 8.6 F 0.9 6.2 F 0.3 6.3 F 0.3 8.0 F 0.2
QFA + VV 277.0 F 41.3 <2 5.3 F 1.1 8.2 F 0.1
Wild-type and IFNgR gko mice were treated with QFA 10 days before
infection with 107 PFU VV iv. Other groups of PBS- and CE-treated mice
were left uninfected. At 3 days postinfection, the mice were sacrificed for
determination of plasma nitrate concentration and viral load in the ovaries.
Results are mean F SEM, n = 3. This experiment is representative of two
similar experiments.
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nonspecific antiviral immunity and the rise in systemic
levels of NO following QFA treatment, experiments were
performed using IFNg receptor gene knockout mice (IFNg
R/) and wild-type controls. In these experiments, mice
were treated with QFA and 10 days later infected intrave-
nously with 107 PFU VV. At 3 days postinfection, plasma
nitrate levels and viral load were assessed. The elevated
plasma nitrate concentration and enhanced virus clearance
following QFA treatment were totally abolished in the IFNg
R/ mice (Table 4). These findings demonstrate that
signaling through the IFNg receptor is essential for the
production of NO and the antiviral effect mediated by
treatment with QFA. These data support the hypothesis that
increased IFNg production in QFA-treated NOS2/ mice
was involved in the enhanced antiviral immunity in these
mutant mice.
Besides NO, numerous alternative IFNg-inducible anti-
viral pathways are known (Shtrichman and Samuel,
2001). To investigate possible pathways that might me-
diate the increased virus clearance in NOS2/ mice,
expression of several candidate genes in the spleen of
QFA-treated, VV-infected NOS2/ and wild-type mice was
examined. Indoleamine 2,3-dioxygenase (IDO), 2V-5V-oligoa-
denylate synthetase (2V-5V OAS), and protein kinase (PKR)
were all up-regulated in QFA-treated mice. Following QFA
treatment and VV infection, IDO expression was markedly
increased in the spleen of NOS2/ mice compared to wild-
type mice (Fig. 1). The difference was approximately 5-fold
(wild type, 1.07 F 0.05 compared to NOS2/, 4.84 F 0.4;
mean F SEM, n = 4 per group, data normalized to HPRT).Fig. 1. IDO expression is increased in QFA-treated NOS2/ following VV infecti
-NOS2+/+ (QFA treated and untreated) mice were isolated and RT-PCR was perfor
by Southern blot analysis using 30-mer oligonucleotide probes for these factors.In contrast, there was little or no difference in expression of
PKR and 2V-5V OAS (data not shown). IDO has previously
been implicated in the control of CMV replication in retinal
pigment epithelial cells (Bodaghi et al., 1999) and in HSV-1
infection in astrocytoma cells (Adams et al., 2004), and we
have recently obtained in vitro evidence that IDO activity
can inhibit VV replication (S. Mahalingam, unpublished
observations). Thus, we hypothesize that increased IDO
expression contributes to the enhanced virus clearance in
QFA-treated NOS2/ mice.
The high levels of NO induced by QFA treatment did not
protect against infection. Indeed, in the absence of NO, virus
clearance was accelerated and this was associated with
increased serum IFNg concentrations, and increased expres-
sion of the IFNg-inducible gene IDO. The results reflect the
complex role of NO in infection. Although NO protects
against infection with a range of viruses such as ectromelia
(Karupiah et al., 1993), herpes simplex virus-1 (Croen,
1993), and Coxsackievirus B3 (Zaragoza et al., 1998),
it does not protect against all viruses (Bartholdy et al.,
1999; Karupiah et al., 1993; Rolph et al., 1996b). We have
previously found that NO production is increased in VV-
infected mice but is not required for effective virus clearance
(Rolph et al., 1996b). However, a recombinant VVencoding
NOS2 was highly attenuated in vivo (Rolph et al., 1996a),
indicating that NO can mediate anti-vaccinia activity in vivo
under appropriate conditions. In the present study, we have
found that high levels of NO production did not protect
against VV infection and were actually detrimental to resis-
tance. Thus, the contribution of NO to virus clearance varies
depending on several variables; these might include locali-
zation andmagnitude of NO production, as well as kinetics of
NO production. Clearly, our findings have important impli-
cations for understanding the immune response to infectious
disease, particularly in cases where one infection is super-
imposed on inflammatory disease or on another infection.Materials and methods
Mice
Female C57BL/6 mice, IFNg-receptor gene knockout
mice (IFNg R/;129/SvEv background) (Huang et al.,
1993), NOS2 gene knockout mice (NOS2/;129/SvEv
background), (MacMicking et al., 1995), and their wild-on. Three days following infection, spleens from VV-infected-NOS2/ and
med for HPRT and IDO. To confirm specificity, PCR products were probed
M.S. Rolph et al. / Virology 326 (2004) 1–54type littermates were bred under specific pathogen-free
conditions at the Animal Breeding Establishment, John
Curtin School of Medical Research. All mice were between
6 and 10 weeks of age. All experiments were approved by
the Animal Experimentation Ethics Committee of the Aus-
tralian National University, Canberra, Australia.
Vaccinia virus and C. burnetii
QFA, a formalin-fixed preparation of C. burnetii (Q fever
complement fixing antigen, phase 1; Nine Mile Strain;
Commonwealth Serum Laboratories, Melbourne, Australia)
was used to treat mice for the induction of nonspecific
antiviral immunity. According to the manufacturer, QFA
contains 1.5 mg/ml of formalin fixed C. burnetii. The
Western Reserve strain of vaccinia virus (VV) was used
and mice were infected at a dose of 107 plaque forming units
(PFU) by the intravenous route. The African green monkey
kidney cell line CV-1 was used for growth of VV stocks.
For virus titration, the human osteosarcoma cell line 143B
was used. All cells were cultured in Eagle’s minimum
essential medium (GIBCO, Grand Island, NY) supple-
mented with 5% FCS, 10 mM HEPES, 1 mM glutamine,
and antibiotics. Organs were homogenized in 1 ml PBS. A
100-Al aliquot of the homogenate was incubated for 30 min
with 100 Al of 1 mg/ml trypsin at 37 jC. Ten-fold serial
dilutions were made in saline containing 0.5% gelatin and
added to cell monolayers grown in six-well plates. The
monolayers were stained with 0.1% crystal violet in 20%
ethanol after 2 days incubation at 37 jC in air containing
5% CO2.
Nitrate and IFNc assays
Systemic NO production was measured indirectly as
nitrate in plasma because this ion constitutes the major
end-stage oxidation product of NO (Rockett et al., 1992).
For nitrate measurements, the nitrate was first converted to
nitrite by incubation with nitrate reductase and NADPH
(Boehringer Mannheim, Mannheim, Germany) for 20 min.
Nitrite was measured by addition of 100 Al of Griess
reagent to 30 Al of test sample. Protein was removed by
addition of 100 Al of trichloroacetic acid followed by
centrifugation, and the OD of the samples was read at
540 nm with a reference at 650 nm using a microplate
reader (Molecular Devices). The results were quantified by
reading against appropriate nitrite and nitrate standard
curves. IFNg ELISA was performed as previously de-
scribed (Mahalingam et al., 1999).
RT-PCR
Total RNA was isolated from spleens by standard
methods with RNAzol B (Biotech Laboratories). An RT-
PCR procedure was performed as previously described
(Mahalingam et al., 1999) to determine the relativequantities of mRNA for various factors. The primers
and probes for all genes were purchased from GIBCO
BRL. Primer and probe sequences for HPRT and IDO
have been described elsewhere (Mahalingam et al., 1999).
After the appropriate number of PCR cycles, the ampli-
fied DNA was analyzed by gel electrophoresis and
Southern blotting, and detected using the enhanced chemi-
luminescence detection system as recommended by the
manufacturer (Amersham Pharmacia Biotech). PCR am-
plification with the HPRT reference gene was performed
to assess variations in cDNA or total RNA loading
between samples.
Statistics
A student’s t test was used for statistical analysis.Acknowledgment
SM is a recipient of the NHMRC Peter Doherty
Fellowship.References
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